Abstract: A pharmaceutical composition comprising an isoxazoline compound complexed with a cyclodextrin such as hydroxy-propyl-cyclodextrin and combined in a dry (anhydrous) composition with polypowder. The composition can be a mixture of isomers, an enriched mixture of a specific enantiomer or a single enantiomer.

Abstract: A topical pain relief composition has a base with a mixture of various components such as, but not limited to, a base, d-limonene, cannabinoids or a derivative thereof, ashwagandha extracts and dimethyl sulfoxide (DMSO).

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 10-20 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: A pain relief composition has a base with cannabinoids in a range of 2% to 15% by weight of the pharmaceutical composition is present with ashwagandha extracts. Dimethyl sulfoxide (DMSO) in a range of 0.01% to 2% by weight of the pharmaceutical composition is further used. The cannaoids are one of cannabidiol (CBD) and tetrahydrocannabinol (THC).

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 10-20 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: A pharmaceutical composition comprising Ivermectin-HPBCD complexed adjuvant formulated for injection or infusion or instillation into a subject, as well as methods for formulating and using the same. The adjuvant composition of the invention in its preferred form comprises an ivermectin-HPBCD complex wherein 1 to 3 grams of the complex is dissolved in 1 ml Tween80 combined with 9 ml sterile distilled water at a pH 6.4. Composition of the present instant invention comprising ivermectin-HPBCD complexed adjuvant formulated for administration via injection or infusion or instillation to a subject find use in treatment and/or prevention of cancer.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 5 or 10 mg of macrocyclic lactone to 1 mL of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: A topical solubilized ivermectin pharmaceutical composition for the treatment and/or prevention of inflammatory skin conditions is disclosed herein. The topical solubilized ivermectin pharmaceutical composition comprises an ivermectin and a cyclodextrin. Particularly, ivermectin is combined with cyclodextrin to form an ivermectin-cyclodextrin complex solubilized in a Tween80-water solution up to a 30% by weight of solution. The present invention features a formulation of Ivermectin-cyclodextrin complex solubilized in a Tween80-water solution incorporated into lotion or cream or gel base that is highly effective in the treatment inflammatory skin conditions at a concentration of, in some embodiments, 0.125% to 5% ivermectin by weight.

Abstract: A computer-implemented method for adaptive behavioral training includes presenting a first visual training area to a user in a visual presentation. The visual presentation is displayed in a coordinate space and the first visual training area is defined by a first set of coordinates in the coordinate space. Measurement data is collected while the first visual training area is presented to the user. This measurement data comprises eye tracking measurement data indicating the user's gaze with respect to the first visual training area. Based on the measurement data, a second visual training area is selected. This second visual training area is defined by a second set of coordinates in the coordinate space that are different than the first set of coordinates. The second visual training area is then presented to the user in the visual presentation.

Abstract: Injectable Ivermectin solution is safely administrable to humans and animals used the disclosed technology. A macrocyclic lactone cyclodextrin complex which is completely dissolvable or dissolved in water in a ratio of at least 50 micrograms to 500 milligrams of the macrocyclic lactone complex per 5 milliliters of water. The macrocyclic lactone cyclodextrin complex is non-toxic, without using organic solvents, and in embodiments, formed by adding a surfactant to the macrocyclic lactone complex to water. The macrocyclic lactone cyclodextrin complex is Ivermectin or an Ivermectin derivative in some embodiments. The cyclodextrin complex is 2-hydroxypropyl-beta-cyclodextrin in some embodiments of the disclosed technology. The surfactant can be polysorbate 80 and is in a ratio of 0.01% to 25%, by weight, to said water. The water soluble complexes can be added to the water. The water-soluble complexes can have at least one of an anti-parasitic, anti-viral and anti-cancer complex.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: Nitric oxide levels in the blood stream are maintained while delivering, in sustained release, medication or therapeutic agent such as an NSAID (e.g. aspirin). This is accomplished by processing, at room temperature or in a low pressure environment without degradation, an amino acid ester with a nitric acid releasing group in an ethyl cellulose-based or other sustained release polymer delivery system. In this manner, in the blood stream nitric oxide levels are maintained at a level to only produce normotension because the nitric oxide is released only during hypertensive moments. The level of nitric oxide release metabolites reaches significance and physiological relevance anywhere between 12 and 48 hours depending upon the individual being dosed level of activity, ambient systolic blood pressure and numerous other factors that create the hypertensive environment that releases nitric oxide from the nitric oxide releasing amino acid ester.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: A pharmaceutical composition for sublingual or buccal administration of melatonin and valerian is complexed with a beta cyclodextrin or another complexation agent. It is then encased in a liposome. The molecules encased in the liposome are then dehydrated and compounded into any of a number of dosage forms such as a dissolvable strip of material, a gum, lozenge, mint, tablet, or powder.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: Described herein are compositions and methods for enhancing or improving sexual performance or for treating sexual dysfunction or impotence comprising administering an effective amount of: a compound of formula (I): wherein n=1 to 10; wherein R1 is an amino acid side chain group (D or L configuration), or derivatives thereof, wherein R2 is a hydrogen atom, or an amino acid (D or L configuration) and derivatives thereof, forming a peptide bond; or any pharmaceutically acceptable salts thereof; and at least one a nutraceutical effective to enhance sexual performance in association with a pharmaceutically acceptable carrier.

Abstract: The present document describes a compressible delivery formulation for transmucosal delivery of at least one compound which includes a micronized powder base; and a desiccated liposome formulation comprising at least one liposome containing at least one compound, process of making the same and process for making dosage forms from the formulation.

Abstract: The present invention features a compressible delivery formulation for buccal delivery, dosage forms and methods of using the same for increasing testosterone levels in a subject. The formulation, dosage forms and methods comprise effective amounts of 3,4-divanillyltetrahydrofuran, 7-methoxyflavone, 7,8-benzoflavone, and L-Dopa.